Clinical efficacy of Tanreqing Injection in the treatment of novel coronavirus infection in maintenance hemodialysis patients

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200059742

Enrollment

Unknown

Registered

2022-05-10

Start date

2022-05-01

Completion date

Unknown

Last updated

2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel coronavirus infection in maintenance hemodialysis patients

Interventions

Experimental group:Daily intravenous drip of Tanreqing Injection

Control group:None

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-90 years old; 2. Meet the above diagnostic criteria for COVID-19; 3. Has received maintenance hemodialysis treatment; 4. All included patients are required to sign an informed consent.

Exclusion criteria

Exclusion criteria: 1. Combined with active malignant tumors; 2. Severe arrhythmia, severe heart failure, NYHA grade III and above; 3. Pregnant or lactating patients; 4. People who cannot cooperate, such as mental patients; 5. Patients who are participating in other clinical trials.

Design outcomes

Primary

Measure	Time frame
Biochemical Indicators;Chest computerized tomography;Nucleic acid detection of novel coronavirus;	—

Countries

China

Contacts

Public ContactHaiying Zhang

Shanghai Sixth People's Hospital

doctormaria@163.com+86 18930174463

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026